- Home
- MLP vs OMER Comparison
MLP vs OMER Comparison
Compare MLP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLP
- OMER
- Stock Information
- Founded
- MLP 1909
- OMER 1994
- Country
- MLP United States
- OMER United States
- Employees
- MLP N/A
- OMER N/A
- Industry
- MLP Real Estate
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- MLP Finance
- OMER Health Care
- Exchange
- MLP Nasdaq
- OMER Nasdaq
- Market Cap
- MLP 344.7M
- OMER 304.9M
- IPO Year
- MLP 1972
- OMER 2009
- Fundamental
- Price
- MLP $17.50
- OMER $4.15
- Analyst Decision
- MLP
- OMER Strong Buy
- Analyst Count
- MLP 0
- OMER 5
- Target Price
- MLP N/A
- OMER $18.00
- AVG Volume (30 Days)
- MLP 15.4K
- OMER 1.0M
- Earning Date
- MLP 08-14-2025
- OMER 08-14-2025
- Dividend Yield
- MLP N/A
- OMER N/A
- EPS Growth
- MLP N/A
- OMER N/A
- EPS
- MLP N/A
- OMER N/A
- Revenue
- MLP $16,843,000.00
- OMER N/A
- Revenue This Year
- MLP N/A
- OMER N/A
- Revenue Next Year
- MLP N/A
- OMER $9,040.39
- P/E Ratio
- MLP N/A
- OMER N/A
- Revenue Growth
- MLP 74.59
- OMER N/A
- 52 Week Low
- MLP $14.05
- OMER $2.95
- 52 Week High
- MLP $26.46
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- MLP 53.69
- OMER 53.72
- Support Level
- MLP $16.41
- OMER $4.06
- Resistance Level
- MLP $17.49
- OMER $4.58
- Average True Range (ATR)
- MLP 0.56
- OMER 0.27
- MACD
- MLP 0.10
- OMER -0.01
- Stochastic Oscillator
- MLP 81.63
- OMER 49.28
About MLP Maui Land & Pineapple Company Inc.
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.